临床试验/NCT02245555

NCT02245555已完成不适用

Observational Study About the Use of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Boehringer Ingelheim0 个研究点目标入组 1,060 人开始时间: 2006年4月最近更新: 2014年9月19日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Boehringer Ingelheim
入组人数: 1,060
主要终点: Number of patients with adverse events

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 21 Years 至 —（Adult, Older Adult）
性别: Male
接受健康志愿者: 否

入选标准

•Patients older than 21 years old diagnosed with benign prostatic hyperplasia (BPH), who require pharmacological treatment to relieve symptoms and improve their quality of life, according to physician's judgment. The study will include naïve patients and patients not responding to previous therapy who receive Secotex as alternative or complementary treatment. The decision to treat a patient with Tamsulosin must be based on the best standard accepted in the clinical practice and must be carried out following Secotex (Tamsulosin) prescription information

排除标准

•Patients with known hypersensitivity to Tamsulosin or any of its ingredients, history of orthostatic hypotension or severe liver failure, or with any missing data required to complete the questionnaire are excluded

研究组 & 干预措施

Patients with benign prostatic hyperplasia

干预措施: Tamsulosin (Drug)

结局指标

主要结局

Number of patients with adverse events

时间窗: up to 21 months

次要结局

未报告次要终点

研究者

发起方

Boehringer Ingelheim

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

1 期

CKD-397 Drug-drug Interaction Study (A)Healthy

NCT02247518Chong Kun Dang Pharmaceutical16

已完成

4 期

Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder SymptomsLower Urinary Tract SymptomsBenign Prostatic Hyperplasia (BPH)Overactive Bladder

NCT02715024Astellas Pharma Taiwan, Inc.52

终止

4 期

Tamsulosin as Adjuvant Treatment Prior to Endoscopic UreterolithotomyUreterolithiasisUrolithiasisUreteral Calculi

NCT03614052Pontificia Universidad Catolica de Chile14

已完成

2 期

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic BladderBladder, Neurogenic

NCT00796614Boehringer Ingelheim231

已完成

1 期

Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.Prostatic Hyperplasia

NCT01471678GlaxoSmithKline27